Jefferies analyst Michael Yee maintains $Biogen (BIIB.US)$ with a buy rating, and maintains the target price at $250.
According to TipRanks data, the analyst has a success rate of 41.5% and a total average return of -1.0% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Biogen (BIIB.US)$'s main analysts recently are as follows:
The strategy to counterbalance the diminishing core franchises involves focusing on developing treatments for conditions that are underserved and challenging to address. The pipeline is perceived to carry a higher clinical risk relative to its major biotech counterparts, which, in turn, presents considerable potential value.
Biogen's collaboration with Eisai on the MAA for lecanemab in amyloid-positive early Alzheimer's disease has seen progress, as the request for reexamination by the EMA's CHMP has resulted in a favorable recommendation, albeit excluding APOE4 homozygotes. This development is perceived as making the application more acceptable to the European Commission, which is anticipated to decide on the approval within a 67-day timeframe.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
富瑞集團分析師Michael Yee維持$渤健公司 (BIIB.US)$買入評級，維持目標價250美元。
根據TipRanks數據顯示，該分析師近一年總勝率為41.5%，總平均回報率為-1.0%。
此外，綜合報道，$渤健公司 (BIIB.US)$近期主要分析師觀點如下：
平衡不斷減少的核心特許經營權的策略包括專注於開發針對服務不足且難以解決的疾病的治療方法。與主要的生物技術同類產品相比，該產品線被認爲具有更高的臨床風險，這反過來又具有可觀的潛在價值。
Biogen與衛材在澱粉樣蛋白陽性的早期阿爾茨海默氏病中對lecanemab的MAA的合作取得了進展，因爲EMA的CHMP要求重新檢查，儘管不包括 APOE4 純合子，但還是提出了積極的建議。這一事態發展被認爲使歐盟委員會更容易接受該申請，預計歐盟委員會將在67天的時間範圍內就批准做出決定。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
